Organized in cooperation with ISSNAF Bay Area Chapter.
A thought provoking conversation about lifespan - the number of years we live - and healthspan - for how many of those years we remain in full health and free from disease. What should we prioritize? Why? How? Leading the discussions are entrepreneurs and researchers at the forefront of this field, moderated by an early investor in the sector.
Panel: Maddalena Adorno, Marco Quarta, Vittorio Sebastiano
Moderator: Pierluigi Zappacosta
*** ABOUT THE SPEAKERS ***
Maddalena Adorno is the co-founder and CEO of Dorian Therapeutics, Inc. and the main inventor of the senoblocker technology that the company is pursuing. In 2019 she was an invited speaker at the Time 100 Health Summit where she presented senoblockers as potential therapeutics for aging. Before founding Dorian, Maddalena completed her postdoctoral training at Stanford University studying Stem Cell and Aging Biology. She was then awarded a Siebel fellowship and received two grants to further advance her research. During her 15 years spent in Academia, she published 13 papers in high-impact journals including Nature, Cell and Science, and her discoveries in stem cell biology were considered amongst the most important research at Stanford University in 2013. Maddalena received her M.Sc. in Medical Biotechnology magna cum laude and a Ph.D. in Biomedicine from University of Padova, Italy. During that time, she co-founded and led the National Council of Biotechnology Students (CNSB) and she served for two years on the executive board of the National Italian Association of Biotechnologists (ANBI).
Marco Quarta is CEO and co-founder of the longevity biotech companies Rubedo Life Sciences and co-founder and director of Turn Biotechnology, leading efforts to develop new therapies targeting ageing to extend healthspan. He earned a Masters degree in Biotechnology at the University of Bologna, Italy, a PhD in Neuroscience at the University of Padova, Italy, and post-doctoral training in Aging, Stem Cells Biology at Stanford University School of Medicine where he then directed a research team focused on translational medical research in the fields of aging and regenerative medicine. He is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University. He also served the European Federation of Biotechnology (EFB) as an executive board member. Prior to that, Quarta founded in Italy the biotech company “WetWare Concepts” , where he served as CEO.
Vittorio Sebastiano is an Associate Professor in the Department of Obstetrics and Gynecology at Stanford School of Medicine. His lab has established a new technology named ERA (Epigenetic Reprogramming of Aging), which repurposes the conceptual idea of reprogramming, with the goal to promote epigenetic rejuvenation of adult cells leaving their identity untouched. This new technology was patented and is being implemented by Turn Biotechnologies, of which Dr. Sebastiano is co-founder and Chair of the Scientific Advisory Board. Dr. Sebastiano completed a postdoctoral fellowship on the newly discovered iPSC technology and was among the first to demonstrate that iPSCs can be efficiently derived, genetically modified, and implemented for cell therapy in genetic diseases. Dr. Sebastiano completed his undergraduate and graduate studies at the University of Pavia, Italy. He joined the Max Planck Institute for Molecular Biomedicine as a postdoctoral fellow where he continued his research on cellular reprograming, germ cells biology, and embryonic development.
Pierluigi Zappacosta received the Laurea degree “cum laude” in electrical engineering from the University of Rome, Italy in 1974, and the Master of Science degree in computer science from Stanford University in 1978. In 1981 he co-founded Logitech, a manufacturer of computer peripherals, where he served for 18 years first as President and CEO and later as Vice Chairman. He helped take Logitech public in Switzerland in 1988 and on NASDAQ in 1997. In 1996 he co-founded DigitalPersona, a biometry-based security company, and was its Chairman for several years. Between 2003 and 2013 he was CEO of Sierra Sciences, a biotech company working to extend the human health span. Currently he is an investor in technology companies in USA and Italy. In 2007 he co-founded ISSNAF (Italian Scientists and Scholars in North America Foundation) and is currently its Secretary and Treasurer. In 2017 he co-founded the ISSNAF Bay Area Chapter and is currently its Chair. He is chairman of "Friends of Istituto Bruno Leoni" in USA and trustee of "Istituto Bruno Leoni" in Italy. On June 2nd, 2003 he received the “Commendatore al Merito della Repubblica”. In October 2015, Pierluigi was knighted “Cavaliere del Lavoro” by the President of the Italian Republic.
*** Safety Protocols ***
- In-person capacity is limited.
- Masks are required in the building.
- We follow best practices laid out by the CDC and state and local guidelines.